Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 4:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 1,760 matching trials from the live ClinicalTrials.gov search.
Conditions
Acute Liver Failure
Interventions
13C-Methacetin
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
11
States / cities
Birmingham, Alabama • San Francisco, California • New Haven, Connecticut + 8 more
Conditions
Acute Kidney Injury, Contrast-induced Nephropathy
Interventions
RENISCHEM L-FABP POC Test
Diagnostic Test
Lead sponsor
Hikari Dx, Inc.
Other
Eligibility
18 Years and older
Enrollment
382 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
6
States / cities
Chandler, Arizona • Concord, California • Clearwater, Florida + 3 more
Conditions
Lung Cancer, Bladder Cancer, Colorectal Cancer, Hepatocellular Carcinoma, Breast Cancer
Interventions
Communication of Patients Lost to Follow-up to Providers
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
21 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
5
States / cities
Chicago, Illinois • Hines, Illinois • Minneapolis, Minnesota + 2 more
Completed No phase listed Observational Accepts healthy volunteers

Tanita BIA System Validation

NCT02118675
Conditions
Body Composition, Circumference Measurements, Tissue Thickness Measurements
Interventions
Body Measurements, Body Composition and Circumference measurements, Whole Body DXA scan, Bioelectrical Impedance Analysis (BIA), BodPod, Circumferences, Ultrasound
Other
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
5 Years to 80 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Conditions
Locally Advanced Extraskeletal Myxoid Chondrosarcoma, Locally Advanced Leiomyosarcoma, Locally Advanced Liposarcoma, Locally Advanced Undifferentiated Pleomorphic Sarcoma, Locally Advanced Unresectable Soft Tissue Sarcoma, Metastatic Soft Tissue Sarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Unresectable Leiomyosarcoma, Unresectable Liposarcoma, Unresectable Undifferentiated Pleomorphic Sarcoma
Interventions
Biopsy Procedure, Biospecimen Collection, Cabozantinib, Computed Tomography, Ipilimumab, Magnetic Resonance Imaging, Nivolumab
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute LAO
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
26
States / cities
Duarte, California • Irvine, California • Los Angeles, California + 19 more
Conditions
Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7
Interventions
Biospecimen Collection, Computed Tomography, Echocardiography Test, Nivolumab, Observation Activity, Positron Emission Tomography
Procedure · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
903 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
884
States / cities
Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 638 more
Completed No phase listed Observational Accepts healthy volunteers

Kenota 1 CWS Method Comparison Validation Study

NCT05702671
Conditions
Allergy, Immunoglobulin E-Mediated Allergic Disorder
Interventions
Total Immunoglobulin E, Obtained From Fingerstick Sample
Diagnostic Test
Lead sponsor
Kenota Inc.
Industry
Eligibility
Up to 80 Years
Enrollment
411 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
3
States / cities
Saint Paul, Minnesota • Chapel Hill, North Carolina • Virginia Beach, Virginia
Conditions
Adult Cystic Nephroma, Anaplastic Kidney Wilms Tumor, Angiolipoma, Cellular Congenital Mesoblastic Nephroma, Classic Congenital Mesoblastic Nephroma, Clear Cell Sarcoma of the Kidney, Congenital Mesoblastic Nephroma, Cystic Partially Differentiated Kidney Nephroblastoma, Diffuse Hyperplastic Perilobar Nephroblastomatosis, Extrarenal Rhabdoid Tumor, Kidney Medullary Carcinoma, Kidney Neoplasm, Kidney Oncocytoma, Kidney Wilms Tumor, Metanephric Adenofibroma, Metanephric Adenoma, Metanephric Stromal Tumor, Metanephric Tumor, Mixed Congenital Mesoblastic Nephroma, Ossifying Renal Tumor of Infancy, Papillary Renal Cell Carcinoma, Renal Cell Carcinoma, Renal Cell Carcinoma Associated With Xp11.2 Translocations/TFE3 Gene Fusions, Rhabdoid Tumor of the Kidney, Wilms Tumor
Interventions
Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 29 Years
Enrollment
8,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2026
U.S. locations
214
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 153 more
Completed No phase listed Observational

SPINCOMS Biomarker Study

NCT04496830
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Prostate Adenocarcinoma, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8
Interventions
Biospecimen Collection, Contrast Agent, Leuprolide, Magnetic Resonance Imaging, Physical Performance Testing, Relugolix
Procedure · Other · Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Advancing Prevention of Pulmonary Fibrosis

NCT04564183
Conditions
IPF, Pulmonary Fibrosis, ILD
Interventions
Sample collection, Questionnaires, High resolution CT scan of the chest, Pulmonary Function Test
Other · Radiation · Diagnostic Test
Lead sponsor
University of Colorado, Denver
Other
Eligibility
40 Years to 75 Years
Enrollment
800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Locally Advanced Pancreatic Carcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Unresectable Pancreatic Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Durvalumab, Magnetic Resonance Imaging, Olaparib
Procedure · Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
10
States / cities
Irvine, California • Los Angeles, California • Orange, California + 5 more
Completed No phase listed Observational Accepts healthy volunteers

COVID-19 Immunity Assessment

NCT05080231
Conditions
COVID-19
Interventions
Not listed
Lead sponsor
DxTerity Diagnostics
Industry
Eligibility
13 Years and older
Enrollment
662 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Compton, California
Conditions
Localized Prostate Carcinoma, Locally Advanced Prostate Carcinoma, Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8, Stage II Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8
Interventions
Biospecimen Collection, Discussion, Exercise Intervention, Interview, Medical Device Usage and Evaluation, Physical Examination, Physical Performance Testing, Questionnaire Administration, Recreational Therapy
Procedure · Other
Lead sponsor
University of Southern California
Other
Eligibility
55 Years to 85 Years · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Los Angeles, California
Conditions
Streptococcus Agalactiae Infection
Interventions
Comparison between GenePOC PCR and Reference Method
Device
Lead sponsor
Meridian Bioscience, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
771 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Detroit, Michigan • Albuquerque, New Mexico
Conditions
Left-Hemisphere Stroke
Interventions
Perfusion functional Magnetic Resonance Imaging (perfusion fMRI)
Diagnostic Test
Lead sponsor
Kessler Foundation
Other
Eligibility
18 Years to 100 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
West Orange, New Jersey
Conditions
High Grade Glioma
Interventions
PET-MRI Brain Scan, Blood draw, Memory testing, Optional lumbar puncture for cerebrospinal fluid collection
Procedure · Diagnostic Test · Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Conditions
Colorectal Carcinoma
Interventions
Biospecimen Collection, Survey Administration
Procedure · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
45 Years and older · Female only
Enrollment
146 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Gestational Diabetes
Interventions
Exenatide, Buccal/blood Sample Collection
Drug · Genetic
Lead sponsor
Georgetown University
Other
Eligibility
18 Years to 50 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
Washington D.C., District of Columbia
Conditions
Pharmacogenetic Testing
Interventions
Panel-based pharmacogenetic genotyping
Diagnostic Test
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 99 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Gainesville, Florida
Conditions
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia, Myelodysplasia-Related
Interventions
Azacitidine, Biospecimen Collection, Bone Marrow Aspiration, Cytarabine, Daunorubicin Hydrochloride, Echocardiography Test, Liposome-encapsulated Daunorubicin-Cytarabine, Multigated Acquisition Scan, Venetoclax
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 59 Years
Enrollment
335 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
215
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 175 more
Conditions
Hereditary Disease, Genetic Predisposition to Disease
Interventions
Whole Genome Sequencing
Genetic
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
3 Months and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Neck Pain
Interventions
Passive Intervertebral Motion testing
Diagnostic Test
Lead sponsor
Florida Gulf Coast University
Other
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Fort Myers, Florida
Conditions
Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Osimertinib, Tegavivint, Echocardiography Test, Multigated Acquisition Scan, Computed Tomography, FDG-Positron Emission Tomography, Biospecimen Collection
Drug · Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
Columbus, Ohio